You can buy or sell RNN and other stocks, options, ETFs, and crypto commission-free!
Rexahn Pharmaceuticals, Inc., also called Rexahn Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. Read More The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 13
Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results
ROCKVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced financial results for the first quarter ended March 31, 2019. First Quarter 2019 and Recent Highlights: Completed enrollment in the Phase 2a clinical trial of RX-3117 in combination with ABRAXANE ® (paclitaxel protein-bound particles for injectable ...
-$0.93 per share
-$0.62 per share